Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research

The European Food Safety Authority (EFSA) is asking for more research on the effects of CBD on humans.

The agency issued a statement earlier this week saying that “the safety of CBD as a novel food cannot currently be established,” as available research on the effects of CBD on the liver, gastrointestinal tract, endocrine system, nervous system, and on psychological well-being is not sufficient.

At the moment, 19 novel food applications are before the agency and the  European Commission has asked the regulatory opinion to render an opinion on the safety of CBD for humans.

“We have identified several hazards related to CBD intake and determined that the many data gaps on these health effects need filling before these evaluations can go ahead,” Dominique Turck, chair of EFSA’s expert panel on Nutrition, Novel Foods and Food Allergens.

EFSA also emphasized that animal studies showed “significant adverse effects” related to reproductive function and that further investigation of whether these effects have been seen in humans is needed.

EFSA plans to hold an information session regarding its statement on June 28.

‘Hars’ FDA Review

In the US, the only cannabis-derived substance approved by the FDA is Epidiolex, a prescription drug that treats rare and severe forms of epilepsy in children, made by Jazz Pharma JAZZ.

All other CBD products intended for use as medication are unauthorized and illegal.

The agency recently sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals.

“Unapproved drugs like these CBD products have not been evaluated by the FDA to determine whether they are effective for their intended use, what the proper dosage might be, how the products could interact with FDA-approved drugs, or whether they have dangerous side effects or other safety concerns,” the agency said in a press release.

The move followed an initial FDA warning to five companies for selling products containing delta-8 THC in violation of the Federal Food, Drug, and Cosmetic Act.

Photo: Courtesy of Kimzy Nanney on Unsplash

 

Posted In: CBDDominique TurckdrugEFSACannabisGovernmentNewsRegulationsEducationEurozoneFDAMarketsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.